THE LUSTGARTEN FOUNDATION AND BREAK THROUGH CANCER ANNOUNCE NEW CLINICAL TRIAL EVALUATING KRAS-TARGETED IMMUNOTHERAPY STRATEGY FOR PANCREATIC CANCER

Phase 1KRAS-targeted immunotherapyPositive

AI Analysis

Summary

The Lustgarten Foundation and Break Through Cancer announced a newly recruiting Phase 1 clinical trial evaluating a next-generation KRAS-targeted immunotherapy strategy for pancreatic cancer, focusing on how the pancreatic tumor microenvironment shapes treatment response.

Clinical Trial Data

Phase

Phase 1

Importance:4/10

Sentiment:

0.50

Phase 1Pancreatic cancerKRAS-targetedImmunotherapyClinical trialTrial initiation

Related Companies

$GBIO

Read the original article

Published by PR Newswire Pharma on August 10, 2026 1:50 PM

Read Original